Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-08-01

FDA Approved: MOVANTIK — Supplemental Application (RedHill Biopharma Ltd)

View source ↗

Summary

The FDA approved a supplemental application for Movantik (naloxegol oxalate) submitted by RedHill Biopharma Ltd.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MOVANTIK (Naloxegol oxalate)

Snippet

SUPPL AP for MOVANTIK (NALOXEGOL OXALATE)